Additionally, NASH diminishes the effectiveness of immunotherapeutic agents such as M30 and aOX40, reducing the infiltration of CD4+ T cells and effector memory cells into the HCC tumor microenvironment (TME) [120]. This evidence concerns the gene CD4 and metabolic dysfunction-associated steatohepatitis.